ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

EHA-NSHBT Sickle Cell Disease Webinar

EHA and the Topics-in-Focus Taskforce on Hemoglobinopathies are working with the Nigerian Society of Haematology and Blood Transfusion (NSHBT) to organize a webinar on Sickle Cell Disease (SCD).

Topics-in-Focus program

Sponsor and Fundraising Committee

Current committee members
Martin Dreyling, Germany (Chair)
Claire Harrison, United Kingdom (Vice-Chair)
Igor Aurer, Croatia (SWG Committee representative)
Arndt Borkhardt, Germany (Research Committee representative)
Konstanze Döhner, Germany (Education Committee representative)
Kirsten Grønbæk, Denmark (Councilor)
Frank Leebeek, The Netherlands (Councilor)
Mariane de Montalembert, France (Councilor)
David Rees, United Kingdom (Education…

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

Meeting chairs, Carlo Balduini and Anna Falanga

The meeting was well attended by more than 100 participants coming from over 20 different countries

Delegate: Great meeting.

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

The 'i4MDS' consortium looks to the future at its second general meeting

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ' i4MDS'—held its second general meeting in The Hague from February 9–10, 2024.